This is a report that provides an update on the Trump Administration's Commission on Combating Drug Addiction and the Opioid Crisis, which includes progress made on the initial 56 recommendations made by the Commission. 

This guide provides practical approaches to prevent addiction-related stigma. These range from simple efforts, such as writing letters to the editor, to more complex efforts, such as implementing community-based stigma prevention campaigns.

This is a report from the O’Neill Institute for National and Global Health Law at Georgetown Law Center (authors LaBelle and Weizman) that provides recommendations for actions that state and local leaders can take immediately to increase evidence-based practices, decrease arbitrary determinations, and prevent overdose deaths in criminal justice and child welfare settings. Multiple case studies are highlighted. 

This is an academic paper that examined initiation of medications for opioid use disorder (MOUD) based on waiting time for an appointment at a low threshold addiction clinic in Boston. Patients who were able to get same-day or next-day appointments were more likely to arrive at their appointments compared with those who had to wait longer. This finding highlights that hospitals should have immediate access to MOUD, such as access a bridge clinic co-located at the hospital, to increase engagement in MOUD. 

The American Society of Addiction Medicine (ASAM) Coronavirus resource page provides information on the addiction treatment system during the Covid pandemic, including guidance to treatment providers, addiction treatment professionals, and accessing medications for opioid use disorder. 

This website provides a report and other resources from the Association of Schools and Programs in Public Health (ASSPH) that makes research-informed recommendations across the entire continuum of care to address the opioid crisis. 

This academic paper provides a summary on state-level policy data relevant to opioid use disorder treament reported by government and non profit agencies that track healthcare regulations. The four areas this report focuses on are tele-health, privacy, licensing, and medication for opioid use disorder (MOUD) during the COVID-19 pandemic. 

This is an academic paper that explores how methadone and buprenorphine capacity vary by race/ethnicity. Study findings show that counties with highly segregated black/African American and Hispanic/Latinx communities had more facilities to provide methadone per capita, while counties with highly segregated white communities had more facilities to provide buprenorphine per capita, highlighting the need for racial equity and justice. 

This is a database from ASTHO entitled “Substance Misuse and Addiction Resources” that is interactive and has thousands of resources, many on opioids.

This is an academic paper which presents a case study of efforts to implement the expansion of access to medication for opioid use disorder (MOUD) in the rural state of Montana. The study identified limits to the hub and spoke model used and offers suggestions for policies that could improve access to MOUD in rural communities such as those in Montana. 

This is a qualitative evaluation of a training program in Washington that waivered physicians to prescribe buprenorphine. Several physicians were interviewed following the program to identify the different barriers to prescribing.

This report describes the importance of integrating behavioral health services, including addiction treatment, into primary health care facilities in order to address substance use disorders in rural areas. Barriers to integration are described, federal resources listed, and recommendations on how communities can facilitate integration are listed.